Newswise — [FORT WASHINGTON, PA — August 23, 2017] The National Comprehensive Cancer Network® (NCCN®) is collaborating with Evinance to integrate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) into the Evinance Decision Support Platform to allow for point-of-care access to treatment recommendations derived from the NCCN Guidelines®.  

“Integration of the NCCN Guidelines into Evinance’s Decision Support system will directly benefit both clinicians and patients by offering evidence-based clinical recommendations at the point of care, as well as empowering patients to partake in the shared decision-making process to determine the best course of treatment for their disease,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN.

Through their health information technology platform, Evinance provides decision support and adherence tracking based on the leading evidence-based guidelines. With integration directly into the clinical workflow, the Evinance Decision Support Platform improves the shared decision-making process by using virtual patient paths to enhance communication so that doctors and patients can choose the best course of action, together.

“Clinicians cannot keep up with the exponential growth of new clinical information, and patients are overwhelmed with what they read online. Most institutions have no centralized, electronic method to provide answers to either group that meet the patient’s needs and that ensure adherence to the latest protocols and treatment plans, which is also critical for reimbursement,” said Chad Armstrong, Chief Executive Officer, Evinance. "This collaboration will ensure the latest evidence-based clinical recommendations are always available at the point of care, enabling better communication with patients.”

The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and most frequently updated clinical practice guidelines available in any area of medicine.

For more information about integration of NCCN Content into Health Information Technology, visit


About Evinance

Evinance believes that the most effective healthcare decisions happen when doctors and patients make them together. Its patented technology provides stateless decision support and adherence tracking based on the leading evidence-based guidelines such as those from the National Comprehensive Cancer Network® (NCCN®). With integration directly into the clinical workflow, the Evinance Decision Support Platform improves the shared decision-making process by using virtual patient paths to enhance communication with the patient.  Headquartered in Montreal, Quebec, Evinance designed their platform to work seamlessly with any EHR, any medical specialty, and any language. For more information, visit or contact them at [email protected]

About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit Patients and caregivers, visit Media, visit